MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Rating of “Hold” from Brokerages

Posted by George Bondi on Aug 17th, 2026

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) have been given a consensus recommendation of “Hold” by the seventeen analysts that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $24.5714.

Several brokerages have recently issued reports on MLTX. Leerink Partners boosted their price objective on MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. HC Wainwright raised their target price on MoonLake Immunotherapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday. Needham & Company LLC raised their target price on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Friday, August 7th. Finally, BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th.

View Our Latest Stock Report on MLTX

Insider Activity at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $20.02, for a total value of $1,367,145.78. Following the transaction, the chief executive officer directly owned 2,774,893 shares of the company’s stock, valued at $55,553,357.86. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the transaction, the insider owned 2,824,551 shares in the company, valued at approximately $54,881,025.93. The trade was a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 344,800 shares of company stock worth $6,820,071. Company insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several large investors have recently modified their holdings of MLTX. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $26,000. Bank of America Corp DE lifted its position in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after buying an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after buying an additional 3,166 shares during the last quarter. Russell Investments Group Ltd. lifted its position in MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Price Performance

Shares of MoonLake Immunotherapeutics stock opened at $16.47 on Monday. The company has a quick ratio of 12.56, a current ratio of 12.56 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.40 billion, a P/E ratio of -4.29 and a beta of 1.06. The firm’s 50 day moving average price is $18.91 and its 200-day moving average price is $17.91. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.84) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.07. On average, sell-side analysts predict that MoonLake Immunotherapeutics will post -3.34 EPS for the current fiscal year.

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.